Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL192942 | 0.93 | HPGD (0.77) | HPGDALDH1A1POLBSMN1; SMN2KMT2A | |
| SCHEMBL3339277 | 0.92 | TSHR (0.67) | HPGDALDH1A1POLBSMN1; SMN2PKM | |
| SCHEMBL5745620 | 0.88 | HPGD (0.71) | HPGDALDH1A1POLBSMN1; SMN2KMT2A | |
| SCHEMBL2436689 | 0.87 | HPGD (0.65) | HPGDALDH1A1POLBSMN1; SMN2KMT2A | |
| SCHEMBL2435315 | 0.86 | HPGD (0.71) | HPGDALDH1A1POLBSMN1; SMN2KMT2A | |
| SCHEMBL7450259 | 0.84 | HPGD (0.61) | HPGDALDH1A1POLBSMN1; SMN2KMT2A | |
| SCHEMBL4085982 | 0.82 | HPGD (0.51) | HPGDALDH1A1POLBSMN1; SMN2PKM | |
| SCHEMBL4097862 | 0.81 | HPGD (0.50) | HPGDALDH1A1POLBSMN1; SMN2PKM | |
| SCHEMBL14409571 | 0.81 | TSHR (0.70) | HPGDALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL5477414 | 0.81 | CYP2C9 (0.68) | HPGDALDH1A1SMN1; SMN2KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278343-B2 | Pyrrolidines | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278343-B2 | Pyrrolidines | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278343-B2 | Pyrrolidines | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2364296-A1 | PYRROLIDINES | Pfizer Limited (GB) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010052625-A1 | PYRROLIDINES | PFIZER LIMITED (GB) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010052625-A1 | PYRROLIDINES | PFIZER LIMITED (GB) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120793-A1 | Pyrrolidines | PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120793-A1 | Pyrrolidines | PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120793-A1 | Pyrrolidines | PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120793-A1 | Pyrrolidines | PTGER2, PTGDR2, PTGES2 | HPGD 24/4885ALDH1A1 289/4885POLB 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.